irinotecan liposome injection + SG001 + fluorouracil + leucovorin

This drug is a **four-drug combination** therapy composed of irinotecan liposome injection, SG001, fluorouracil, and leucovorin. **Irinotecan liposome injection** is a liposomal formulation of irinotecan, a topoisomerase-1 inhibitor that interferes with DNA replication in cancer cells. **SG001** is a code name and limited public information is available; it likely refers to an investigational or region-specific version/formulation of liposomal irinotecan, similar to HR070803 or LY01610, both of which are novel liposomal irinotecan hydrochloride products tested in China[1][3]. **Fluorouracil** is a pyrimidine analog and antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. **Leucovorin** is a reduced folate that enhances the binding of fluorouracil to its target enzyme and helps rescue normal cells from toxicity. This combination has established efficacy in the treatment of **advanced or metastatic pancreatic cancer** and is administered after disease progression on gemcitabine-based regimens[5][7][3]. Each component targets DNA synthesis or repair in different ways, providing synergistic anti-tumor effects.